Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 2 — POCT-DOAC 2  

Anticoagulation With Direct Oral Anticoagulants Clinical Trial

Official title: Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 2

Status Completed

Clinical Trial Summary

The investigators study aims to test the correlation between the Hemochron Signature point-of-care testing (POCT) device (ITC, USA) and low plasma levels of all three currently approved direct oral anticoagulants (DOAC; rivaroxaban, apixaban and dabigatran) and to determine the diagnostic accuracy of POCT to rule out or detect relevant levels of DOAC in real-life stroke patients.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Anticoagulation With Direct Oral Anticoagulants

• NCT number: NCT02371070
• Study type: Observational
• Source: University Hospital Tuebingen
• Status: Completed
• Phase: N/A
• Start date: December 2013
• Completion date: May 2016